巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    23andMe Holding Co

    ME
    3.010
    0.240
    8.47%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・23andMe Holding Co - 延遲價格・最後更新於 26/09 12:00
    最高位
    3.010
    最低位
    2.700
    開市價
    --
    前收市價
    2.775
    成交量(千)
    349.84
    成交額(百萬)
    6.57
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    1,359.09
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    13.680 - 2.120
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    23andMe Holding Co
    證券代碼
    ME.US
    所屬板塊
    Diagnostics & Research
    公司業務
    23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    發行量
    448812321
    公司總部
    349 Oyster Point Boulevard
    公司網址
    https://www.23andme.com
    公司電話
    +1 650 938-6300
    暫無內容

    關於

    23andMe Holding Co(ME.US)所屬的行業板塊為Diagnostics & Research。
    23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    詳細公司背景可參考: https://www.23andme.com